Brokerages expect that ProNAi Therapeutics, Inc. (NASDAQ:SRRA) will report earnings of ($0.21) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for ProNAi Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.18). ProNAi Therapeutics reported earnings per share of ($0.43) during the same quarter last year, which would suggest a positive year over year growth rate of 51.2%. The firm is scheduled to announce its next earnings results on Friday, August 11th.
According to Zacks, analysts expect that ProNAi Therapeutics will report full-year earnings of ($0.90) per share for the current fiscal year, with EPS estimates ranging from ($0.99) to ($0.82). For the next year, analysts expect that the business will post earnings of ($0.82) per share, with EPS estimates ranging from ($0.98) to ($0.68). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow ProNAi Therapeutics.
ProNAi Therapeutics (NASDAQ:SRRA) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.07.
Separately, Zacks Investment Research downgraded shares of ProNAi Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 11th.
Several large investors have recently bought and sold shares of SRRA. VHCP Management II LLC bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $200,000. FMR LLC bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $302,000. Greenleaf Trust bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $328,000. Nexthera Capital LP bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $612,000. Finally, PNC Financial Services Group Inc. bought a new position in shares of ProNAi Therapeutics during the first quarter valued at about $1,142,000. 60.29% of the stock is currently owned by institutional investors and hedge funds.
ProNAi Therapeutics (NASDAQ SRRA) opened at 1.16 on Wednesday. The stock’s market cap is $60.63 million. ProNAi Therapeutics has a 52 week low of $1.10 and a 52 week high of $2.25. The company’s 50 day moving average is $1.19 and its 200 day moving average is $1.38.
ProNAi Therapeutics Company Profile
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with our FREE daily email newsletter.